BI/Lilly's Jentadueto wins EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has approved Boehringer Ingelheim/Lilly’s antidiabetic Jentadueto, which combines the DDP-4 inhibitor linagliptin (Trajenta/Tradjenta) and metformin in a single pill. It is approved for use along with diet and exercise to improve glycaemic control in adults with type 2 diabetes who are inadequately controlled on their maximal tolerated dose of metformin alone, or for those already being treated with linagliptin and metformin with or without an insulin secretagogue such as sulphonylurea.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.